Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells $421,440.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the sale, the insider now directly owns 141,782 shares in the company, valued at $19,917,535.36. This trade represents a 2.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The shares were sold at an average price of $146.04, for a total value of $149,837.04.
• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Stock Performance

Natera stock opened at $133.87 on Friday. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market cap of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80. The firm’s fifty day moving average price is $156.81 and its 200-day moving average price is $151.40.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. On average, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Trading of Natera

Hedge funds have recently bought and sold shares of the company. 111 Capital purchased a new position in shares of Natera during the fourth quarter worth approximately $397,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Natera by 79.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,493 shares of the medical research company’s stock valued at $3,086,000 after purchasing an additional 8,635 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Natera in the 4th quarter worth $19,210,000. HWG Holdings LP lifted its stake in Natera by 173.0% in the fourth quarter. HWG Holdings LP now owns 40,739 shares of the medical research company’s stock worth $6,449,000 after purchasing an additional 25,819 shares during the last quarter. Finally, Polar Asset Management Partners Inc. boosted its position in Natera by 1.6% during the fourth quarter. Polar Asset Management Partners Inc. now owns 96,105 shares of the medical research company’s stock valued at $15,213,000 after buying an additional 1,500 shares during the period. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Guggenheim lifted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Barclays began coverage on Natera in a research note on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective on the stock. Morgan Stanley raised their target price on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.